The NeurologyLive staff compiled highlights from our discussions with experts in one convenient location, following ECTRIMS 2021.
The 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), October 13-15, featured hundreds of presentations, conversations, and updates with experts in the care of patients with multiple sclerosis (MS).
The virtual conference covered topics such as the use of integrative medicine (IM) in MS and the latest data for investigational agents, such as ATA188 in progressive MS, data on the efficacy and safety of ublituximab (TG Therapeutics), as well as results from a phase 2 study that evaluated autologous mesenchymal stromal cells secreting neurotrophic factors cells in patients with progressive MS.
The NeurologyLive team sat down with several leaders in the MS field, learning more about key findings, while also gaining additional insight into areas for future research, the use of telehealth, and takeaways from ECTRIMS 2021 overall.
Click here for more coverage of multiple sclerosis from NeurologyLive, or for more coverage of ECTRIMS 2021, click here.